HomeComparePROCF vs PFE

PROCF vs PFE: Dividend Comparison 2026

PROCF yields 1818.18% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROCF wins by $4103414683.79M in total portfolio value
10 years
PROCF
PROCF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PROCF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — PROCF vs PFE

📍 PROCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROCF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PROCF beats the other by $3,147,377,270,419,817.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROCF + PFE for your $10,000?

PROCF: 50%PFE: 50%
100% PFE50/50100% PROCF
Portfolio after 10yr
$2051707341.94M
Annual income
$1,851,398,394,391,808.80/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PROCF
No analyst data
Altman Z
0.4
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROCF buys
0
PFE buys
0
No recent congressional trades found for PROCF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCFPFE
Forward yield1818.18%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4103414683.84M$51.1K
Annual income after 10y$3,702,796,788,756,407.00$27,210.54
Total dividends collected$4074760433.31M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PROCF vs PFE ($10,000, DRIP)

YearPROCF PortfolioPROCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$192,518$181,818.18$9,161$701.38+$183.4KPROCF
2$3,477,331$3,271,336.99$8,610$859.79+$3.47MPROCF
3$58,943,217$55,222,471.89$8,366$1,081.25+$58.93MPROCF
4$937,891,469$874,822,227.57$8,483$1,405.66+$937.88MPROCF
5$14,012,869,532$13,009,325,660.38$9,084$1,907.24+$14012.86MPROCF
6$196,647,994,247$181,654,223,846.76$10,418$2,732.78+$196647.98MPROCF
7$2,592,865,386,485$2,382,452,032,641.56$13,007$4,193.56+$2592865.37MPROCF
8$32,132,661,421,271$29,358,295,457,731.54$18,010$7,005.87+$32132661.40MPROCF
9$374,409,247,740,494$340,027,300,019,734.44$28,216$12,979.89+$374409247.71MPROCF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$51,081$27,210.54+$4103414683.79MPROCF

PROCF vs PFE: Complete Analysis 2026

PROCFStock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PROCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PROCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROCF vs SCHDPROCF vs JEPIPROCF vs OPROCF vs KOPROCF vs MAINPROCF vs JNJPROCF vs MRKPROCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.